Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC

PD-L1 IHC 22C3 pharmDx Can Now Be Used to Identify a Broader Range of NSCLC Patients for First-line Treatment With KEYTRUDA® (pembrolizumab)

QR Code
Embed the QR code on your website:
Download
Copy